<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669901</url>
  </required_header>
  <id_info>
    <org_study_id>15-616</org_study_id>
    <nct_id>NCT02669901</nct_id>
  </id_info>
  <brief_title>Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder</brief_title>
  <official_title>Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaleo Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot-study is to to distribute naloxone auto-injector in a &quot;Universal
      Precaution&quot; manner to patients with opioid substance use disorder. The objectives are to
      decrease the number of fatal and nonfatal overdose deaths, to examine and understand the risk
      factors for serious opioid toxicity and overdose, and to evaluate the unintentional opioid
      overdose risk utilizing an evidence-based screening questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of fatal over dose deaths by use of naloxone auto-injector co-prescribing from the University of New Mexico Addiction and Substance Abuse Program (UNM ASAP)</measure>
    <time_frame>2 years</time_frame>
    <description>Patients on chronic opioid therapy will be co-prescribed a naloxone-autoinjector rescue kit to decrease the accidental overdose rate associated with these medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of near fatal overdoses prevented by use of naloxone auto-injector co-prescribing from the University of New Mexico Addiction and Substance Abuse Program (UNM ASAP)</measure>
    <time_frame>2 years</time_frame>
    <description>Patients on chronic opioid therapy will be co-prescribed a naloxone-autoinjector rescue kit to decrease the accidental overdose rate associated with these medications.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Opiate Antagonist Overdose</condition>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Patients with opioid substance abuse disorders</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Naloxone Auto-Injector</intervention_name>
    <description>Naloxone auto-injector is the only product FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.</description>
    <arm_group_label>Patients with opioid substance abuse disorders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients treated with methadone, naltrexone or buprenorphine as medication
             assisted treatment at the UNM Addiction and Substance Abuse Program (UNM ASAP) aged 18
             or older

        Exclusion Criteria:

          -  Subjects who are allergic to naloxone and its inactive ingredients. Inactive
             ingredients include buffering agents.

          -  Subjects younger than 18.

          -  Subjects not being treated at UNM ASAP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joanna Katzman, MD</last_name>
    <phone>505-272-3342</phone>
    <email>JKatzman@salud.unm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikiko Yamada-Takeda, Pharm.D.</last_name>
    <phone>505-272-6126</phone>
    <email>MYamada@salud.unm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UNM Hospitals - Alcohol and Substance Abuse Program</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Snehal Bhatt, MD</last_name>
      <phone>505-994-7999</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Joanna G Katzman</investigator_full_name>
    <investigator_title>Dr. Joanna Katzman</investigator_title>
  </responsible_party>
  <keyword>Opioid-Related Disorders</keyword>
  <keyword>Naloxone</keyword>
  <keyword>Harm Reduction</keyword>
  <keyword>Drug Overdose Deaths</keyword>
  <keyword>Opioid Misuse</keyword>
  <keyword>Naloxone Coprescribing</keyword>
  <keyword>Universal Precautions</keyword>
  <keyword>Opioid Substance Use Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

